Wells Fargo & Company Ultragenyx Pharmaceutical Inc. Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 31,408 shares of RARE stock, worth $1.41 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
31,408
Previous 41,756
24.78%
Holding current value
$1.41 Million
Previous $2 Million
26.55%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding RARE
# of Institutions
291Shares Held
78.6MCall Options Held
570KPut Options Held
228K-
Vanguard Group Inc Valley Forge, PA8.7MShares$390 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY7.09MShares$318 Million5.31% of portfolio
-
Black Rock Inc. New York, NY5.24MShares$235 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA4.1MShares$184 Million0.03% of portfolio
-
Sands Capital Management, LLC Arlington, VA3.86MShares$173 Million0.53% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $3.14B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...